Table 3.
Correlations between clinicopathological characteristics and the status of TERTp mutations.
| Total | TERTp | P value | ||
|---|---|---|---|---|
| Mut | Wt | |||
| n = 147 (%) | n = 59 (%) | n = 88 (%) | ||
| Sex | 0.041 | |||
| Male | 84 (57.1) | 40 (67.8) | 44 (50.0) | |
| Female | 63 (42.9) | 19 (32.2) | 44 (50.0) | |
| Age (years) | <0.001∗ | |||
| <45 | 70 (47.6) | 17 (28.8) | 53 (60.2) | |
| 45-60 | 59 (40.1) | 31 (52.5) | 28 (31.8) | |
| ≥60 | 18 (12.2) | 11 (18.6) | 7 (8.0) | |
| Tumor location | 0.729 | |||
| Frontal | 91 (61.9) | 38 (64.4) | 53 (60.2) | |
| Others | 56 (38.1) | 21 (35.6) | 35 (39.8) | |
| Histology | 0.007∗ | |||
| DA | 37 (25.2) | 8 (13.6) | 29 (33.0) | |
| AA | 15 (10.2) | 4 (6.8) | 11 (12.5) | |
| AO | 24 (16.3) | 16 (27.1) | 8 (9.1) | |
| OA | 6 (4.1) | 1 (1.7) | 5 (5.7) | |
| O | 28 (19.0) | 14 (23.7) | 14 (15.9) | |
| GBMs | 37 (25.2) | 16 (27.1) | 21 (23.9) | |
| Pathologic stage | 0.338 | |||
| Grade II-III | 109 (74.1) | 41 (69.5) | 68 (77.3) | |
| Grade IV | 38 (25.9) | 18 (30.5) | 20 (22.7) | |
| Ki-67 | 0.392 | |||
| <15% | 89 (60.5) | 33 (55.9) | 56 (63.6) | |
| ≥15% | 58 (39.5) | 26 (44.1) | 32 (36.4) | |
| IDH gene | 0.312 | |||
| Mutation | 76 (51.7) | 34 (57.6) | 42 (47.7) | |
| Wild type | 71 (48.3) | 25 (42.4) | 46 (52.3) | |
| MGMT promoter | 0.088 | |||
| Methylated | 108 (73.5) | 48 (81.4) | 60 (68.2) | |
| Unmethylated | 39 (26.5) | 11 (18.6) | 28 (31.8) | |
TERTp: the promoter region of the telomerase reverse transcriptase gene; IDH: isocitrate dehydrogenase; MGMT: O6-methylguanine-DNA methyltransferase; Mut: mutation; Wt: wild-type; DA: diffuse astrocytoma; AA: anaplastic astrocytoma; AO: anaplastic oligodendroglioma; OA: oligoastrocytoma; O: oligodendroglioma; GBMs: glioblastomas. P value was calculated by the Pearson chi-square test or the 2-tailed Fisher's exact test. ∗Statistically significant: P < 0.05.